CNAs at the level of MYC, MYCN, GSK3B, MTOR, and BRCA2 are more frequently detected in germline BRCA2-mutant prostate cancers than in sporadic localized cancers [30,418]. This evidence concerns the gene MYCN and prostate carcinoma.